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function cannot be fully evaluated. 
Because Treg homing remains intact, we 
propose that a defect in Treg function (but 
not necessarily homing) might account 
for the results observed with the CCR4–/− 
mice. To test this hypothesis, in vitro T-cell 
suppressor assays may be performed 
using Tregs isolated from oxazolone-
treated skin of WT and CCR4–/− mice.
Additional hypotheses may explain 
the unexpected results presented by 
Lehtimäki et al. (2010). As discussed 
previously, multiple cell types, including 
endothelial cells, DCs, and keratino-
cytes, produce CCL17. CCR4 may be 
dispensable with respect to recruitment 
of T cells into the skin (section 1 in Figure 
1), with CCR10 playing a compensatory 
role in the absence of CCR4, but events 
downstream of initial recruitment may be 
important. Secretion of CCL17 by DCs 
is believed to mediate DC–T-cell inter-
actions. Upon maturation, DCs have 
been shown to produce CCL17, which 
mediates attraction and adhesion of these 
DCs to antigen-primed T cells (Wu et al., 
2001). In particular, these interactions 
may be important for the in situ develop-
ment of effector and regulatory T-cell acti-
vation (section 2 in Figure 1). The lack of 
interaction between DCs and Tregs due 
to lack of CCR4 on Tregs is another possi-
ble explanation for the enhanced inflam-
mation seen in CCR4–/− mice. Finally, 
keratinocytes also synthesize CCL17, 
which may be important for epidermo-
tropism of both memory effector T cells 
and Tregs (section 3 in Figure 1). Correct 
localization of T-cell populations within 
the epidermis might alter inflammatory 
responses. For these reasons, future stud-
ies should address events downstream of 
tissue homing: specifically Treg/DC and 
T-cell/keratinocyte interactions.
It is becoming clearer that chemokine 
receptors are not always positive media-
tors of skin inflammation, but that they 
can be critical for suppression of inflam-
mation as well. What complicates the 
picture is that some receptors, as exem-
plified by CCR4, may act in both ways. 
Depending on the model of inflamma-
tion used, CCR4’s effects can influence 
inflammation in different, almost con-
tradictory, ways. Indeed, the nuances 
and complexities of chemokine receptor 
function in the skin are just beginning to 
be discerned at a fine level.
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Paying “Particle” Attention to novel 
Melanoma Treatment Strategies
Michele B. Weiss1 and Andrew E. Aplin1
Malignant melanoma remains the deadliest form of skin cancer because of its high-
ly aggressive nature and the lack of effective treatments. Recent invest igations into 
alternative treatment strategies have highlighted the exciting potential of nanopar-
ticles to increase melanoma cell delivery and the efficacy of small inter fering RnAs 
(siRnAs) and pharmacological inhibitors. In this issue, Chen et al. report a new 
liposomal nanoparticle for c-Myc siRnA delivery, noting it to be highly effective 
in reducing c-Myc expression and inhibiting melanoma tumor growth in mouse 
models. This preclinical study underscores the importance of investigating nano-
particle treatment options for chemoresistant melanomas.
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Introduction
The field of targeted therapeutic strat egies 
for melanoma is entering exciting times. 
Malignant melanoma is the deadliest form 
of skin cancer and has for decades repre-
sented a paradigm for chemoresistance. 
Current therapeutic options are poor and 
no new US Food and Drug Administration 
(FDA)-approved drugs have emerged in 
recent years. Current melanoma treatment 
mainstays, such as the alkylating agent 
dacarbazine and the immune-stimulating 
agent IL-2, are plagued by a lack of clini-
cal benefit in the majority of patients and 
numerous side effects. However, highly 
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encouraging results have been reported 
recently, renewing hope that new FDA-
approved drugs will be forthcoming. 
The phase I trial of the RAF inhibitor, 
RG7204/PLX4032 (Plexxikon), found 
that approximately 75% of mutant 
B-RAF melanoma patients displayed 
responses by RECIST criteria (Flaherty 
et al., 2009). Additionally, a phase III 
study of ipilimumab (Bristol–Myers 
Squibb), an anticytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) drug, 
improved overall median survival for 
metastatic melanoma patients that had 
received previous treatment (Hodi et 
al., 2010). Although the outlook appears 
promising, major difficulties remain. For 
example, the majority of patients who 
initially responded to RG7204 have 
subsequently relapsed, raising concerns 
about acquired/secondary resistance. 
Also, despite the improved median sur-
vival data for ipilimumab, the response 
rate was only 11%. Hence, additional 
targeted therapies are needed urgently.
In this issue, Chen et al. focus on tar-
geting c-Myc, a proto-oncogene that is 
well studied in cancer. c-Myc is a basic 
helix–loop–helix leucine zipper tran-
scription factor that is highly expressed 
in melanoma (Ross and Wilson, 1998). 
Importantly for the current study, c-Myc 
depletion in melanoma cells induces cell 
cycle arrest and a senescence-like phe-
notype (Zhuang et al., 2008). Conversely, 
overexpression of c-Myc in normal mel-
anocytes inhibits mutant B-RAF-induced 
senescence (Zhuang et al., 2008). These 
effects may result from alterations in the 
expression of several c-Myc transcrip-
tional target genes that encode rate-
limiting enzymes for dNTP metabolism 
(Mannava et al., 2008).
nanoparticle-based melanoma  
treatment strategies
Chen et al. (2010, this issue) used a 
c-Myc small interfering RNA (siRNA) 
depletion strategy combined with a 
unique liposomal nanoparticle formu-
lation to increase siRNA stability and 
cell delivery. They developed nanopar-
ticles formed from a DSAA carrier lipid, 
instead of the previously utilized DOTAP 
liposome particles, which were targeted 
specifically to melanoma cell sigma 
receptors via an anisamide ligand (DSAA 
AA+). Compared with DOTAP AA+ 
nanoparticles, the DSAA AA+ particles 
containing c-Myc siRNA increased cell 
delivery and c-Myc reduction in vivo. In 
addition, dose-dependent tumor growth 
inhibition was seen after intravenous 
administration of DSAA AA+ c-Myc 
siRNA particles in the syngeneic B16F10 
mouse melanoma tumor model and in 
a human melanoma xenograft system. 
Perhaps the most striking finding was the 
complete growth inhibition of B16F10 
mouse melanoma tumors when the 
DSAA AA+ c-Myc siRNA particles were 
administered in combination with pacli-
taxel chemotherapy. Interestingly, the 
biological properties of the DSAA car-
rier lipid itself seem to add an additional 
dimension to the potency of this mela-
noma treatment strategy. Empty DSAA 
nanoparticles were shown to increase 
reactive oxygen species (ROS) levels, 
decrease expression of the prosurvival 
protein Bcl-2, and increase apoptosis in 
B16F10 cells. Importantly, all treatments 
with DSAA nanoparticles were dem-
onstrated to have low immunotoxicity. 
Taken together, these results highlight the 
potential of utilizing DSAA AA+ cationic 
nanoparticles to target gene expression 
as a new melanoma treatment option. 
These results, along with the possible 
chemotherapeutic drug combination ave-
nues they open, may one day offer hope 
to patients with advanced melanomas, 
especially those who may have acquired 
resistance to other treatments.
Chen and colleagues (2010) are not 
the first to utilize nanoparticles as a 
siRNA delivery vehicle to target mela-
nomas in preclinical assays. Tran et 
al. (2008) utilized topical applications 
of liposomal nanoparticles combined 
with ultrasound to promote B-RAFV600E-
selective and Akt3 siRNAs to penetrate 
into the skin microenvironment and 
inhibit the growth of mutant B-RAF mel-
anoma cells in 3-D in vitro and xenograft 
assays. These studies utilized DOTAP/
DOPE/DSPE-PEG(2000)-formulated 
nanoparticles that might lack the ROS-
generating effects observed with the 
DSAA-formulated nanoparticles used in 
the Chen et al. experiments. In a sepa-
rate study, investigators delivered sys-
temically protease-activated receptor-1 
siRNA incorporated into neutral DOPC 
liposomal nanoparticles (Villares et al., 
2008). Importantly, protease-activated 
receptor-1 siRNA-containing liposomes 
decreased growth and metastasis of 
human melanoma cells in nude mice.
Nonliposomal nanoparticles have also 
been used to deliver siRNAs and pharma-
cologic inhibitors into primary and meta-
static melanomas. Similar to the Chen 
et al. study in this issue, Zamora-Avila 
and colleagues (2009) used the B16F10 
mouse melanoma tumor model but 
instead focused on the treatment of mela-
noma lung metastases. They formulated 
Wilms’ tumor gene 1 siRNA-polyethylen-
imine nanoparticles and introduced them 
into the murine lung via an aerosol-based 
delivery system. Strikingly, these nano-
particles decreased lung tumor burden 
and increased survival without lung tissue 
damage or acute inflammatory response 
(Zamora-Avila et al., 2009). Yet another 
study expanded the scope of the use of 
nanoparticles to include pharmaco logical 
drug delivery with particular focus on the 
improvement of sustained and targeted 
drug release. Basu et al. (2009) derived 
nanoparticles composed of a hexaden-
tate–polylactic acid–glycolic acid poly-
mer conjugated to the MAP/ERK kinase 
pharmacologic inhibitor, PD98059. This 
formulation demonstrated increased 
inhibition of melanoma cell prolifera-
tion both in vitro and in vivo compared 
with traditional drug delivery methods 
(Basu et al., 2009). In addition, PD98059-
conjugated nanoparticles could syner-
gize with cisplatin treatment to demon-
strate enhanced antitumor activity in the 
B16F10 mouse melanoma model.
Clinical Implications
•  Malignant melanoma is a paradigm for resistance to chemotherapy.
•  Nanoparticle delivery of siRNAs represents a selective approach to 
target any expressed mRNA in melanoma cells.
•  c-Myc expression is elevated in melanoma, and targeting c-Myc shows 
promise in in vivo preclinical assays.
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concluding remarks
Given the scarcity of effective treat-
ment options available for patients with 
advanced melanoma, the dawn of nano-
particle delivery systems could not come 
at a better time. Future studies in the field 
should focus on potential com binations 
of siRNA- and chemotherapeutic/ phar-
macological inhibitor-containing nano-
particles because both formulations have 
been shown to increase delivery and 
effectivenesss. In addition, although syn-
geneic mouse models such as B16F10 
are highly important in the development 
of cancer therapies, it would be advanta-
geous to extend these studies into mod-
els more relevant to human melanoma 
progression. Specifically, the recent 
conditional B-RAFV600E/PTEN-deficient 
metastatic melanoma mouse is an ideal 
disease model for preclinical studies 
of these nanoparticles (Dankort et al., 
2009). Additional studies with human 
melanoma xenograft mice, which allow 
for representation of a wide range of mel-
anoma genetic backgrounds and staging, 
would also be of value.
In conclusion, increasing evidence 
from the past several years has revealed 
nanoparticles to have the potential to 
improve the efficacy of current treat-
ments and/or to open doors to strategies 
such as siRNA targeting, which until now 
have been plagued with problems. The 
work of Chen et al. (2010) extends this 
area of research and demonstrates that 
targeting melanoma tumor cells with 
c-Myc siRNA packaged within the new 
DSAA nanoparticle, alone or in combi-
nation with chemotherapy, can inhibit 
melanoma tumor growth in several sys-
tems, offering hope for the development 
of potent and efficacious treatment strat-
egies for advanced melanoma.
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Oxygenation State as a Driver  
of Myofibroblast Differentiation  
and Wound Contraction:  
Hypoxia Impairs Wound Closure
Chandan K. Sen1 and Sashwati Roy1
Myofibroblasts are ubiquitous in the human body and may form from the 
differentiation of fibroblasts, epithelial cells, endothelial cells, and mononuclear 
cells, among others. Their clinical significance could be substantial, depending on 
biomedical context. Myofibroblasts help contract open skin wounds, but they could 
also be key drivers of fibrosis across numerous tissue systems and support tumor 
invasiveness. Understanding the molecular events underlying myofibroblast forma-
tion is significant for many human diseases. In this issue, Modarressi et al. address the 
significance of wound tissue hypoxia in impairing wound contraction by compro-
mising myofibroblast formation. They present compelling evidence indicating tissue 
hypoxia conflicts with wound closure. We are reminded that correcting wound tis-
sue hypoxia is critical for the tissue’s response to other therapeutic interventions.
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In 1977, Packer reported that human 
diploid fibroblasts grown at 10% O2 live 
longer than cells grown at the routine 
20% O2 (Packer and Fuehr, 1977). The 
field of cellular senescence was in its 
infancy, with the concept of the “Hayflick 
limit” reported in 1961. In 2003, Roy et 
al. (2003a) reported that growth arrest 
of fibroblasts caused by 20% O2 was 
reversible, consistent with the current 
study (Modarressi et al., 2010), and it 
was therefore concluded that exposure of 
cells to hyperoxic insult causes differen-
tiation, but not senescence. Although it 
is standard practice to culture cells at an 
ambient O2 concentration of 20% (i.e., 
